Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
INNOSUISSE
Numéro de projet
8557.1;6 LSPP-LS
Titre du projet
Development of New Methodology to Optimize Peptide-based Drug Discovery
Titre du projet anglais
Development of New Methodology to Optimize Peptide-based Drug Discovery
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Description succincte
-
-
Résumé des résultats (Abstract)
-
-
Textes saisis
Catégorie
Texte
Description succincte
(Anglais)
Development of New Methodology to Optimize Peptide-based Drug Discovery
Description succincte
(Français)
Development of New Methodology to Optimize Peptide-based Drug Discovery
Résumé des résultats (Abstract)
(Anglais)
Dr Hartley's lab is a world leader in the field of peptide and protein engineering. Recent work has focussed on adapting molecular diversity technologies such as phage display in order to develop proteins and peptides as candidate medicines. The project aims are (i) to develop new molecular diversity strategies related to peptide drug discovery, and (ii) to test them, alongside existing approaches, as tools to develop novel peptide-based drugs. Evaluation of the approaches will be performed in collaboration with GENKYOTEX, a CTI start-up company whose mission is to develop new drugs that inhibit NOX enzymes. Such drugs could be used to treat diseases for which effective therapies are currently lacking.
Résumé des résultats (Abstract)
(Français)
Dr Hartley's lab is a world leader in the field of peptide and protein engineering. Recent work has focussed on adapting molecular diversity technologies such as phage display in order to develop proteins and peptides as candidate medicines. The project aims are (i) to develop new molecular diversity strategies related to peptide drug discovery, and (ii) to test them, alongside existing approaches, as tools to develop novel peptide-based drugs. Evaluation of the approaches will be performed in collaboration with GENKYOTEX, a CTI start-up company whose mission is to develop new drugs that inhibit NOX enzymes. Such drugs could be used to treat diseases for which effective therapies are currently lacking.
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales